These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9694740)

  • 61. [Interferon-alpha in the treatment of chronic myeloid leukemia].
    Guilhot F
    Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
    [No Abstract]   [Full Text] [Related]  

  • 62. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
    Cacciola E; Cacciola RR; Guglielmo P; Stagno F; Giustolisi R
    Haematologica; 1999 Aug; 84(8):755-6. PubMed ID: 10457418
    [No Abstract]   [Full Text] [Related]  

  • 64. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
    Najean Y
    Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hydroxyurea-induced fever and hepatitis.
    Westerman DA; Schwarer A; Grigg AP
    Aust N Z J Med; 1998 Oct; 28(5):657-9. PubMed ID: 9847957
    [No Abstract]   [Full Text] [Related]  

  • 66. A clinical update in polycythemia vera and essential thrombocythemia.
    Tefferi A; Solberg LA; Silverstein MN
    Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pathogenesis and management of essential thrombocythemia.
    Beer PA; Green AR
    Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
    Löfvenberg E; Wahlin A
    Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
    Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
    Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CHROMOSOME STUDIES IN CHRONIC MYELOID LEUKAEMIA.
    BLOCK M
    Br Med J; 1965 Apr; 1(5440):994. PubMed ID: 14260639
    [No Abstract]   [Full Text] [Related]  

  • 72. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
    Boqué C; Grañena A
    Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
    [No Abstract]   [Full Text] [Related]  

  • 73. Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.
    Bouscary D; Jondeau K; Viguié F; Zompi S; Fontenay-Roupie M; Quarre MC; Vassilief D; Dreyfus F; Casadevall N
    Leuk Lymphoma; 1999 May; 33(5-6):607-11. PubMed ID: 10342591
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
    Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
    Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.
    Shvidel L; Sigler E; Haran M; Klepfish A; Duek A; Berrebi A; Shtalrid M
    Leukemia; 2007 Sep; 21(9):2071-2. PubMed ID: 17611572
    [No Abstract]   [Full Text] [Related]  

  • 77. [Polycythemia vera: current status of therapy].
    Lengfelder E; Hehlmann R
    Dtsch Med Wochenschr; 2000 Oct; 125(41):1243-7. PubMed ID: 11076265
    [No Abstract]   [Full Text] [Related]  

  • 78. Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndrome.
    Liu TC; Suri R
    Blood; 1998 Aug; 92(4):1465-6. PubMed ID: 9694744
    [No Abstract]   [Full Text] [Related]  

  • 79. The myeloproliferative disorders. An historical appraisal and personal experiences.
    Michiels JJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
    Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
    Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.